NTLA vs. BMY
Compare and contrast key facts about Intellia Therapeutics, Inc. (NTLA) and Bristol-Myers Squibb Company (BMY).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: NTLA or BMY.
Key characteristics
| NTLA | BMY | |
|---|---|---|
| YTD Return | -32.50% | 9.27% |
| 1Y Return | -29.16% | -2.27% |
| 3Y Return (Ann) | -46.06% | 0.86% |
| 5Y Return (Ann) | 13.54% | 3.74% |
| Sharpe Ratio | -0.50 | -0.07 |
| Sortino Ratio | -0.43 | 0.09 |
| Omega Ratio | 0.95 | 1.01 |
| Calmar Ratio | -0.34 | -0.03 |
| Martin Ratio | -1.25 | -0.13 |
| Ulcer Index | 24.36% | 15.26% |
| Daily Std Dev | 61.11% | 26.83% |
| Max Drawdown | -90.02% | -98.62% |
| Current Drawdown | -88.36% | -48.71% |
Fundamentals
| NTLA | BMY | |
|---|---|---|
| Market Cap | $2.09B | $108.20B |
| EPS | -$5.78 | -$3.25 |
| PEG Ratio | -0.10 | 2.05 |
| Total Revenue (TTM) | $33.98M | $35.54B |
| Gross Profit (TTM) | $26.40M | $24.47B |
| EBITDA (TTM) | -$385.36M | $13.74B |
Correlation
The correlation between NTLA and BMY is 0.21, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
NTLA vs. BMY - Performance Comparison
In the year-to-date period, NTLA achieves a -32.50% return, which is significantly lower than BMY's 9.27% return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
NTLA vs. BMY - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Intellia Therapeutics, Inc. (NTLA) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
NTLA vs. BMY - Dividend Comparison
NTLA has not paid dividends to shareholders, while BMY's dividend yield for the trailing twelve months is around 4.50%.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NTLA Intellia Therapeutics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
BMY Bristol-Myers Squibb Company | 4.50% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% | 2.46% | 3.31% |
Drawdowns
NTLA vs. BMY - Drawdown Comparison
The maximum NTLA drawdown since its inception was -90.02%, smaller than the maximum BMY drawdown of -98.62%. Use the drawdown chart below to compare losses from any high point for NTLA and BMY. For additional features, visit the drawdowns tool.
Volatility
NTLA vs. BMY - Volatility Comparison
Intellia Therapeutics, Inc. (NTLA) has a higher volatility of 14.79% compared to Bristol-Myers Squibb Company (BMY) at 5.56%. This indicates that NTLA's price experiences larger fluctuations and is considered to be riskier than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
NTLA vs. BMY - Financials Comparison
This section allows you to compare key financial metrics between Intellia Therapeutics, Inc. and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities